Supernus Pharmaceuticals Gestion
Gestion contrôle des critères 3/4
Le PDG Supernus Pharmaceuticals est Jack Khattar, nommé en Jan2005, a un mandat de 21.33 ans. La rémunération annuelle totale est $ 12.65M, composée du salaire de 8% et des bonus 92%, y compris les actions et options de la société. détient directement 3.82% des actions de la société, d'une valeur de $ 105.23M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6.3 ans et 13.8 ans.
Informations clés
Jack Khattar
Directeur général
US$12.6m
Rémunération totale
| Pourcentage du salaire du PDG | 7.95% |
| Durée du mandat du directeur général | 21.3yrs |
| Propriété du PDG | 3.8% |
| Durée moyenne d'occupation des postes de direction | 6.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 13.8yrs |
Mises à jour récentes de la gestion
Recent updates
SUPN: Resolved Supply Constraints Will Support Future Repricing Potential
Analysts have lifted their price target on Supernus Pharmaceuticals by $5 to $65, citing refreshed models after Q4 results and improved visibility on Onapgo supply as production ramps up with the current supplier and a second source expected in 2027. Analyst Commentary Bullish Takeaways Bullish analysts view the $65 price target, up from $60, as reflecting refreshed forecasts after the latest Q4 update.SUPN: Resolved Supply Constraints And Dual Sourcing Plans Will Support Future Repricing
Narrative Update: Supernus Pharmaceuticals Analyst Price Target Shift Analysts have lifted their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models after Q4 results and expectations that Onapgo supply constraints are now addressed with increased production capacity and a planned second supplier in 2027. Analyst Commentary Analysts see the updated price target as a reflection of fresh Q4 inputs and improved visibility on Onapgo supply.SUPN: Resolved Supply Constraints Will Support Repricing Through Improved Execution
Analysts have lifted their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models after Q4 results and expectations that Onapgo supply constraints are easing with increased production capacity and an additional supplier planned for 2027. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$65 price target as a reflection of updated models that better align with recent Q4 information and current expectations for the business.SUPN: Supply Resolution And Refined P/E Assumptions Will Support Repricing
Analysts have increased their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models following Q4 results and expectations that Onapgo supply constraints are now resolved with expanded production capacity. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$65 price target as a reflection of updated Q4 assumptions that support their view of improved execution and earnings potential.SUPN: Stable Fair Value And Refined P/E Assumptions Will Support Repricing
Analysts modestly adjusted their $61.33 price target on Supernus Pharmaceuticals as they updated their assumptions around revenue growth, profit margin, and future P/E. This reflects a more finely tuned view of the company’s earnings power and valuation risk.SUPN: Steady Fair Value And P/E Outlook Will Support Bullish Repricing
Analysts have kept their price target for Supernus Pharmaceuticals broadly steady, citing only modest tweaks to underlying assumptions such as a slightly higher discount rate, minor adjustments to expected revenue growth and profit margin, and a largely unchanged future P/E outlook. Valuation Changes Fair Value Estimate remains unchanged at 61.33.Supernus: Outlook For 2026 Positive, Upholding Buy Rating
Feb 01SUPN: Higher 2025 Revenue Guidance Will Support Expanded Future Earnings Multiple
Analysts have adjusted their price target on Supernus Pharmaceuticals to US$61.33 per share, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E that remain broadly in line with prior estimates. What's in the News Supernus Pharmaceuticals raised its 2025 total revenue guidance to a range of US$685 million to US$705 million, including approximately US$75 million to US$85 million from Trokendi XR and Oxtellar XR (Key Developments).SUPN: Higher 2025 Revenue Guidance Will Support Expanded Future Earnings Multiple
Analysts have inched their price target on Supernus Pharmaceuticals higher by about $0.83, citing updated assumptions that include a modest adjustment to fair value, slightly different revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Supernus Pharmaceuticals raised its 2025 total revenue guidance to a range of US$685 million to US$705 million, including approximately US$75 million to US$85 million from Trokendi XR and Oxtellar XR (Key Developments).SUPN: Faster Therapy Adoption Will Drive Shares Toward Higher Future Upside
Analysts have raised their price target on Supernus Pharmaceuticals to $65, up from $40, citing a faster than expected ramp for ONAPGO and the potential for additional upside beyond current peak sales assumptions. Analyst Commentary Recent research updates reflect a constructive shift in sentiment toward Supernus, with multiple firms lifting price targets and emphasizing the upside from ONAPGO's adoption curve.SUPN: Upgrades Will Drive Future Upside As Revenue Outlook Tightens
Analysts have raised their price target on Supernus Pharmaceuticals to $65 from $40, reflecting growing confidence in stronger ONAPGO uptake and expanded long term earnings potential. Analyst Commentary Recent Street research reflects a more constructive stance on Supernus, with higher price targets supported by improving ONAPGO assumptions and a clearer long term earnings trajectory.SUPN: Upgrades Will Drive Momentum As Earnings Guidance Increases
Analysts have raised their price target for Supernus Pharmaceuticals from $59.33 to $60.50, citing improved revenue growth expectations and increased peak sales forecasts for ONAPGO. Analyst Commentary Recent Street research reflects growing optimism around Supernus Pharmaceuticals, as analysts adjust their targets and ratings in response to strong expectations for ONAPGO and the company’s broader growth trajectory.SUPN: Upgrades And Revenue Outlook Will Shape Performance Amid Execution Risk
Analysts have raised their price target for Supernus Pharmaceuticals by over $4 to approximately $59.33 per share. This change is due to higher future revenue growth expectations and an improved outlook for key therapies.Analysts Boost Price Targets for Supernus Pharmaceuticals on Accelerating Growth and Revenue Outlook
Supernus Pharmaceuticals’ analyst price targets have risen sharply, with the fair value estimate increasing from $49.20 to $55.20 per share as analysts cite accelerating growth prospects and higher peak sales potential in key product lines. Analyst Commentary Bullish Takeaways Bullish analysts have raised their price targets substantially, with figures as high as $65 per share.Widening CNS Access Will Shape Long-term Market Opportunity
Analysts have raised their fair value estimate for Supernus Pharmaceuticals from $40.20 to $49.20, citing a stronger forecast for blockbuster products and higher projected profit margins. This has resulted in a more than $9 increase in their price target.We Ran A Stock Scan For Earnings Growth And Supernus Pharmaceuticals (NASDAQ:SUPN) Passed With Ease
Sep 10
Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price
Jul 23Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality
May 13Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking
Feb 10Supernus: New Approval Holds Promise Of Increased Growth
Feb 06Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
Nov 12Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk
Oct 31
Qelbree And GOCOVRI Spearhead Robust Revenue Surge, Setting The Path For Market Domination In CNS Therapeutics
Supernus Pharmaceuticals shows robust growth potential with advancements in its product pipeline and significant net sales growth from key products like Qelbree and GOCOVRI.Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
Sep 12Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings
Aug 19Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout
Jul 02Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price
Apr 24Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Mar 04We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
May 10Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?
Feb 03Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$39m |
| Sep 30 2025 | n/a | n/a | -US$19m |
| Jun 30 2025 | n/a | n/a | US$64m |
| Mar 31 2025 | n/a | n/a | US$62m |
| Dec 31 2024 | US$13m | US$1m | US$74m |
| Sep 30 2024 | n/a | n/a | US$60m |
| Jun 30 2024 | n/a | n/a | US$5m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$13m | US$963k | US$1m |
| Sep 30 2023 | n/a | n/a | US$26m |
| Jun 30 2023 | n/a | n/a | US$43m |
| Mar 31 2023 | n/a | n/a | US$52m |
| Dec 31 2022 | US$10m | US$914k | US$61m |
| Sep 30 2022 | n/a | n/a | US$38m |
| Jun 30 2022 | n/a | n/a | US$57m |
| Mar 31 2022 | n/a | n/a | US$73m |
| Dec 31 2021 | US$8m | US$870k | US$53m |
| Sep 30 2021 | n/a | n/a | US$82m |
| Jun 30 2021 | n/a | n/a | US$100m |
| Mar 31 2021 | n/a | n/a | US$111m |
| Dec 31 2020 | US$7m | US$836k | US$127m |
| Sep 30 2020 | n/a | n/a | US$129m |
| Jun 30 2020 | n/a | n/a | US$118m |
| Mar 31 2020 | n/a | n/a | US$116m |
| Dec 31 2019 | US$8m | US$812k | US$113m |
Rémunération vs marché: La rémunération totale de Jack ($USD 12.65M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 7.20M ).
Rémunération et revenus: La rémunération de Jack a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Jack Khattar (64 yo)
21.3yrs
Titularisation
US$12,648,993
Compensation
Mr. Jack A. Khattar, M.B.A., founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 21.3yrs | US$12.65m | 3.82% $ 105.2m | |
| Senior VP & CFO | 4.8yrs | US$2.29m | 0.014% $ 394.0k | |
| Chief Scientific Officer & Senior VP of Intellectual Property | 14.2yrs | US$1.28m | 0.030% $ 815.6k | |
| Senior VP & Chief Technology Operations Officer | 6.3yrs | US$1.35m | 0.032% $ 882.2k | |
| Senior VP of Research & Development and Chief Medical Officer | 6.3yrs | US$1.48m | 0.023% $ 638.4k | |
| Compliance Officer | 14.3yrs | pas de données | pas de données | |
| Senior Vice President of Sales | 11.3yrs | pas de données | pas de données | |
| Senior VP & Chief Commercial Officer | less than a year | pas de données | pas de données | |
| Senior VP & Chief Business Officer | less than a year | pas de données | pas de données | |
| Senior Vice President of Supply Chain | 5yrs | pas de données | pas de données |
6.3yrs
Durée moyenne de l'emploi
64yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de SUPN est chevronnée et expérimentée (6.3 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 21.3yrs | US$12.65m | 3.82% $ 105.2m | |
| Independent Chairman of the Board | 21.3yrs | US$399.69k | 0.22% $ 5.9m | |
| Independent Director | 11.2yrs | US$381.19k | 0.047% $ 1.3m | |
| Independent Director | 7.9yrs | US$368.69k | 0.047% $ 1.3m | |
| Independent Director | 16.3yrs | US$377.69k | 0.10% $ 2.9m | |
| Independent Director | 2.8yrs | US$355.19k | pas de données |
13.8yrs
Durée moyenne de l'emploi
64.5yo
Âge moyen
Conseil d'administration expérimenté: Le conseil d'administration de la SUPN est chevronné et expérimenté ( 13.8 années d'ancienneté moyenne).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/03 14:07 |
| Cours de l'action en fin de journée | 2026/05/01 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Supernus Pharmaceuticals, Inc. est couverte par 17 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Emily Bodnar | Berenberg |
| Chi Meng Fong | BofA Global Research |
| Pavan Patel | BofA Global Research |